We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

77 hedge funds and large institutions have $165M invested in Protagonist Therapeutics in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 28

1% more capital invested

Capital invested by funds: $164M → $165M (+$1.52M)

0.41% more ownership

Funds ownership: 85.25% → 85.66% (+0.41%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 81 → 77 (-4)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
77
Holders Change
-4
Holders Change %
-4.94%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
31
Reduced
28
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$4.68M
2
BBA
Baker Bros. Advisors
New York
+$3.78M
3
NHAS
Novo Holdings A/S
Denmark
+$1.64M
4
RI
RTW Investments
New York
+$1.5M
5
Invesco
Invesco
Georgia
+$636K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.78M
2
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$1.76M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.12M
4
O
OrbiMed
New York
-$931K
5
SFM
Sphera Funds Management
Israel
-$779K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$28.9M +$98.7K +13,177 +0.3%
RI
2
RTW Investments
New York
$18.8M +$1.5M +200,404 +8%
JJIJ
3
Johnson & Johnson Innovation - JJDC
New Jersey
$17.3M – – –
BBA
4
Baker Bros. Advisors
New York
$11.9M +$3.78M +504,882 +43%
BlackRock
5
BlackRock
New York
$11M -$33.7K -4,501 -0.3%
FCM
6
Farallon Capital Management
California
$10.6M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$7M +$12.6K +1,684 +0.2%
JP Morgan Chase
8
JP Morgan Chase
New York
$6.23M +$4.68M +624,546 +242%
NHAS
9
Novo Holdings A/S
Denmark
$4.93M +$1.64M +218,825 +46%
BI
10
BVF Inc
California
$4.89M +$73.4K +9,800 +1%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$4.76M +$21.7K +2,897 +0.4%
Renaissance Technologies
12
Renaissance Technologies
New York
$4.06M -$320K -42,724 -7%
SFM
13
Sphera Funds Management
Israel
$3.71M -$779K -103,925 -16%
Citadel Advisors
14
Citadel Advisors
Florida
$3.31M +$75.8K +10,119 +2%
Millennium Management
15
Millennium Management
New York
$2.42M -$3.78M -504,819 -60%
State Street
16
State Street
Massachusetts
$2.24M -$153K -20,378 -6%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$2.07M +$172K +22,998 +8%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$1.98M -$1.12M -149,983 -35%
Northern Trust
19
Northern Trust
Illinois
$1.81M +$77.2K +10,304 +4%
GTC
20
Ghost Tree Capital
New York
$1.61M -$353K -47,173 -17%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.59M -$707K -94,300 -30%
IC
22
Ikarian Capital
Texas
$1.12M +$599K +79,896 +102%
VA
23
VR Adviser
New York
$799K +$848K +113,140 New
Two Sigma Investments
24
Two Sigma Investments
New York
$774K -$706K -94,261 -46%
Russell Investments Group
25
Russell Investments Group
United Kingdom
$736K +$426K +56,872 +120%
1
2 3 4

PTGX Hedge Fund Activity: Q1 2020 in Review

77 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2020, worth a combined $165M — up 0.93% from $164M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PTGX and 8 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 31 added.

The largest buyer was JP Morgan Chase, adding an estimated $4.68M. The largest seller was Millennium Management, cutting an estimated $3.78M.

  • 77 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2020, down from 81 in Q4 2019.
  • Funds reported $165M of Protagonist Therapeutics stock for Q1 2020, up 0.93% quarter-over-quarter.
  • 8 funds opened new Protagonist Therapeutics positions in Q1 2020 and 9 closed out, a net change of -1 holder.
  • The largest Protagonist Therapeutics buyer in Q1 2020 was JP Morgan Chase, an estimated $4.68M added.
  • The largest Protagonist Therapeutics seller in Q1 2020 was Millennium Management, an estimated $3.78M sold.

Based on aggregated 13F filings for Q1 2020.